Project Grant P01CA291694
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$2.7M
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $714,317 to the Icahn School of Medicine at Mount Sinai to conduct research on the tumor microenvironment and mechanisms driving prostate cancer progression to metastatic castration-resistant disease. The research aims to: Determine how epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) signaling within the tumor microenvironment impact anoikis...
The National Cancer Institute (NCI) awarded a $2,489,032 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research. The 5-year award, effective August 1, 2025, will support three highly integrated research projects focused on determining the roles, regulation, and underlying mechanisms of lipid metabolism in ferroptosis, a form of iron-dependent cell death, and exploring novel cancer therapeutic approaches based on these...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $147,083 to the Icahn School of Medicine at Mount Sinai to conduct research on "Deconstructing Pathogenic Myelopoiesis in Cancer Immunosuppression and Treatment Resistance." The goal is to study the epigenetic regulation and priming of key regulatory pathways in tumor-educated bone marrow myeloid progenitors, which contribute to immunosuppression and therapy...
This Project Grant award from the National Cancer Institute (CFDA 93.396, Cancer Biology Research) provides $680,334 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at understanding the fundamental biological mechanisms underlying age-associated pathogenic myelopoiesis and its contribution to increased cancer risk and progression in aging populations. The 5-year study will utilize high-dimensional profiling, multi-omics phenotyping, and complex bone marrow experiments to...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award of $560,297 to the Icahn School of Medicine at Mount Sinai supports research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The key objectives are to: Generate phenotypic transcriptional reporters to track the dynamics of LGR5+ cancer stem cells (CSCs) and ONFSCs, and use these to dissect the functional interplay between these stem cell populations. Employ a multi-omic...
The National Cancer Institute (NCI) awarded a $701,538 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Icahn School of Medicine at Mount Sinai (ISMMS) to conduct research on understanding the evolution and maintenance of distinct epigenomic subtypes of small cell lung cancer (SCLC), a highly aggressive lung cancer subtype. The project aims to elucidate the mechanistic roles of lineage factors, particularly NKX2-1, in the development and adaptation of...
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
This federal Project Grant award of $532,970.00, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to define the key cell-intrinsic features and cell interactions of anti-tumor CD4 T cells that promote anti-tumor immunity and enhance responses to PD-1 targeted immunotherapy. The 5-year project, awarded to the Icahn School of Medicine at Mount Sinai, aims to study the transcriptional programs and secreted factors in...
The National Cancer Institute (NCI) awarded a $238,722 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research in New York. The grant, awarded on August 18, 2025, will fund research to investigate the role of mutagenic DNA repair mechanisms, such as microhomology-mediated end joining (MMEJ), in driving acquired drug resistance in persister cancer cells. The research aims to define the specific mechanisms by which...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $507,000 Project Grant to the Icahn School of Medicine at Mount Sinai. The grant, effective from Sep 1, 2025 to Aug 31, 2027, will support research to investigate tumor-intrinsic epigenetic mechanisms modulating antitumor immune responses in metastatic prostate cancer. As a leading academic medical center, the Icahn School of Medicine at Mount Sinai has a strong track record of...